PATENT CLAIM ANALYSIS

Application Number: 15957601
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2019-10
Patent Classification: ["514", "547000"]

Abstract:
Therapeutic solutions for axonal degeneration include use of NRF2 activators in prevention and/or treatment of axonal degeneration. A method of prevention and/or treating axonal degeneration includes administering a therapeutically effective amount of a NRF2 activator selected from a GSK3 inhibitor or the compound of formula (I): wherein R 1  and R 2 , which may be the same or different, independently represent H, a linear, branched wherein R 1  and R 2 , which may be the same or different, independently represent a linear, branched or cyclic, saturated or unsaturated C 1-6  alkyl radical, a pharmaceutical salt thereof or a metabolite or precursor of the dimethyl fumarate to a patient in need of the treatment.

Claim (Index 4):
The method according  claim 3 , wherein the X-ALD is adrenomyeloneuropahy (AMN).

Metadata:
- Claim Count in Document: 21.0
- Percentile: 91.0
- Lexical Diversity: 1.81429
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13799636', '15512392', '15356766', '15730832', '12513197']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6909724601266375
- 35 USC 102 Novelty (BERT): 0.5074661369833877
- Combined Prediction Score: 0.6726218278123125
- Mean Citation Score: 166.885454
- Max Citation Score: 258.06293
- Similarity Product: 185.09540310907303

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test